Pfizer (Biosimilars Infliximab Portfolio) Overview
- Status
- Acquired/Merged
- Latest Deal Type
- Asset Purch.
- Financing Rounds
- 1
Pfizer (Biosimilars Infliximab Portfolio) General Information
Description
European Rights of Remicade biosimilar products. The asset is the rights to develop and manufacture the product, infliximab (PF-06438179), which is a tumor necrosis factor alpha (TNF-alpha) inhibitor designed to treat a range of autoimmune diseases, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and plaque psoriasis.
Contact Information
- 235 East 42nd Street
- New York, NY 10017
- United States
Pfizer (Biosimilars Infliximab Portfolio) Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Pfizer (Biosimilars Infliximab Portfolio)‘s full profile, request access.
Request a free trialPfizer (Biosimilars Infliximab Portfolio) Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Pfizer (Biosimilars Infliximab Portfolio)‘s full profile, request access.
Request a free trial